Lytic Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control  by Migueles, Stephen A. et al.
Immunity
ArticleLytic Granule Loading of CD8+ T Cells
Is Required for HIV-Infected Cell Elimination
Associated with Immune Control
Stephen A. Migueles,1 Christine M. Osborne,1 Cassandra Royce,1 Alex A. Compton,1 Rohan P. Joshi,1 Kristin A. Weeks,1
Julia E. Rood,1 Amy M. Berkley,1 Jonah B. Sacha,2 Nancy A. Cogliano-Shutta,1 Margaret Lloyd,1 Gregg Roby,1
Richard Kwan,1 Mary McLaughlin,1 Sara Stallings,1 Catherine Rehm,1 Marie A. O’Shea,1 JoAnn Mican,1
Beverly Z. Packard,3 Akira Komoriya,3 Sarah Palmer,4 Ann P. Wiegand,4 Frank Maldarelli,4 John M. Coffin,4
John W. Mellors,5 Claire W. Hallahan,1 Dean A. Follman,1 and Mark Connors1,*
1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
2Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53719, USA
3OncoImmunin, Gaithersburg, MD 20877, USA
4HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
5Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA
*Correspondence: mconnors@nih.gov
DOI 10.1016/j.immuni.2008.10.010SUMMARY
Virus-specific CD8+ T cells probably mediate control
over HIV replication in rare individuals, termed long-
term nonprogressors (LTNPs) or elite controllers.
Despite extensive investigation, the mechanisms re-
sponsible for this control remain incompletely under-
stood. We observed that HIV-specific CD8+ T cells
of LTNPs persisted at higher frequencies than those
of treated progressors with equally low amounts of
HIV. Measured on a per-cell basis, HIV-specific
CD8+ T cells of LTNPs efficiently eliminated primary
autologous HIV-infected CD4+ T cells. This function
required lytic granule loading of effectors and deliv-
ery of granzyme B to target cells. Defective cytotoxic-
ity of progressor effectors could be restored after
treatment with phorbol ester and calcium ionophore.
These results establish an effector function and
mechanism that clearly segregate with immunologic
control of HIV. They also demonstrate that lytic gran-
ule contents of memory cells are a critical determi-
nant of cytotoxicity that must be induced for maximal
per-cell killing capacity.
INTRODUCTION
Encouragement for the ultimate development of effective
vaccines and immunotherapies that would limit HIV replication
canbedrawn frompatientswhoare naturally occurring examples
of immune system-mediated control. These rare individuals
contain HIV for many years without antiretroviral therapy (ART)
(Migueles et al., 2000). Although definitions and terms have
varied, individualswithin our cohort (referred to as long-termnon-
progressors [LTNPs] or elite controllers) have been infected for
amedian of 17 years yet have remained clinically well, with stable
CD4+ T cell counts and viral loads of <50 copies/ml. Direct andImmindirect lines of evidence in humans and animal models suggest
that virus-specific CD8+ T cells mediate this control, although the
mechanisms by which this occurs remain unknown (reviewed in
Migueles et al., 2004) (Friedrich et al., 2007; Maness et al., 2008).
Over the past 10 years, new tools have permitted an extensive
characterization of the HIV-specific T cell response of LTNPs
(reviewed in Migueles et al., 2004) (Bailey et al., 2006; Emu
et al., 2005; Migueles et al., 2000; Navis et al., 2007; Tilton
et al., 2007). The HIV-specific CD8+ T cells of LTNPs maintain
greater frequencies of ‘‘polyfunctional’’ cells, named for their abil-
ity to degranulate and to produce several cytokines, including
interleukin-2 (IL-2) (Betts et al., 2006; Zimmerli et al., 2005). How-
ever, these cells make up an extremely small subset of the total
HIV-specific CD8+ T cell response, and many LTNPs demon-
strate few or no such cells. HIV-specific CD8+ T cells of LTNPs
maintain greater proliferative capacity than those of progressors
and upregulate perforin upon stimulation (Arrode et al., 2005;
Horton et al., 2006;Migueles et al., 2002). However, the relevance
of differences in in vitro proliferative capacity to the in vivo situa-
tion is unclear given the similar frequencies of HIV-specific CD8+
T cells between LTNPs and untreated progressors (Migueles
et al., 2002).
Cytotoxicity has been explored in some prior work but has not
thus far distinguished patients with immunologic control of HIV
(Caoet al., 1995;Klein et al., 1995; Pantaleo et al., 1995). Interpre-
tation of theseearly studies is complicatedby the lackof sensitive
viral-load assays that would permit recruitment of homogeneous
cohorts with clear immunologic control of HIV, by comparisons
to patients with a global decline in immunity, and by the use of
chromium-release-based assays that are neither highly quantita-
tive nor highly reproducible in humans. More recently, the ability
of CD8+ T cells of LTNPs to diminish HIV replication in humanized
mice or in vitro was used as a measure of suppression of HIV
replication (de Quiros et al., 2000; Saez-Cirion et al., 2007).
However, such assays are not sufficiently powerful to establish
whether the mechanism responsible for differences in function
is determined by precursor frequency, precursor proliferation,
preferential target or effector cell death, Fas-mediated killing, or
secretion of chemokines, TNF, or suppressor factors. For theseunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Inc. 1009
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laboratories in this field or in current vaccine trials.
Furthermore, the relationship between changes in lytic granule
contents after stimulation and killing by virus-specific memory
CD8+ T cells has remained poorly understood. It has been an ac-
cepted paradigm for some time that memory cells maintain full
cytotoxic capacity (reviewed in Seder and Ahmed, 2003; Tram-
bas and Griffiths, 2003). Barber et al. observed that lymphocytic
choriomeningitis virus (LCMV)-specific memory cells in immune
mice retained the ability to kill peptide-pulsed targets in 1–4 hr,
suggesting that upregulation of effector molecules is not neces-
sary for killing by memory cells (Barber et al., 2003). On the basis
of this model, re-expansion of memory cells does not involve
qualitative changes in cytotoxic capacity but rather is primarily
quantitative. More recently, other results have suggested that
cytolytic capacity may be related to the effector molecule con-
tent of memory CD8+ T cells (Wolint et al., 2004; Meng et al.,
2006; Migueles et al., 2002; Sandberg et al., 2001). However,
this has been largely unexplored, in part because of the lack of
reagents for staining of some lytic granule proteins in mice and
the need for assays that measure killing on a per-cell basis.
Thus, whether changes in lytic granule contents translate into
qualitative changes in killing capacity has not been established.
In the present study, we examine the frequency and cytotoxic
function of HIV-specific CD8+ T cells and their mechanism of
killing autologous HIV-infected CD4+ T cells. We observed that
HIV-specific CD8+ T cells of LTNPs exhibited extraordinary cyto-
toxic capacity on a per-cell basis against HIV-infected cells.
CD8+ T cells of progressors lysed HIV-infected cells poorly,
even at high true effector:target (E:T) ratios. These findings sug-
gest that CD8+ T cell loading and delivery of cytotoxic proteins to
HIV-infected CD4+ T cells is an HIV-specific effector mechanism
that clearly segregates with LTNPs. Perhaps most importantly,
they demonstrate that lytic granule contents of memory cells
are a critical determinant of cytotoxicity that must be restimu-
lated for maximal per-cell killing capacity.
RESULTS
Relationship between CD8+ T Cell Frequencies
and Amounts of HIV RNA
We first examined the relationship between frequency of HIV-
specific CD8+ T cells and amount of viral antigen. The frequency
of HIV-specificCD8+T cells in the peripheral blood of LTNPs is no
different from that of untreated progressors (Betts et al., 2001;
Gea-Banacloche et al., 2000; Migueles et al., 2002). In contrast,
progressors with HIV RNA amounts suppressed to <50 copies/
ml plasma byART (Rx < 50) have considerably lower HIV-specific
CD8+ T cell frequencies in the peripheral blood than do LTNPs or
untreated progressors (Gray et al., 1999; Migueles et al., 2002).
It has been presumed that these differences between LTNPs
and Rx < 50 are due to greater virus replication in LTNPs below
the detection threshold in standard assays. We examined the
relationship between viral replication and CD8+ T cell frequency
in these patient populations (Tables S1 and S2 available online)
by using a newer assay with a lower detection limit of 1 copy/ml
(Palmer et al., 2003). We observed that the median HIV-1 RNA
amount of Rx < 50 was not significantly different from those
of LTNPs (1 versus 2 copies/ml, respectively, p = 0.3;1010 Immunity 29, 1009–1021, December 19, 2008 ª2008 ElsevierFigure 1A), consistent with some recent observations (Dinoso
et al., 2008).
The median frequency of HIV-specific CD8+ T cells producing
interferon-g (IFN-g) in response to autologous HIVSF162-infected
CD4+ T cells was 20-fold lower in Rx < 50 than in LTNPs (0.14%
versus 2.8%, respectively, p < 0.001; Figure 1B). HIV RNA was
not detected in this assay in some LTNPs or Rx < 50. However,
even when the analysis was limited to 19 LTNPs and 28 ART re-
cipients with plasma viremiaR1 copy/ml, the median frequency
of HIV-specific CD8+ T cells was still significantly lower in Rx < 50
than in LTNPs (0.13% versus 3.24%, respectively, p < 0.001),
despite similar amounts of plasma viral RNA (medians: 5 versus
4.7 copies/ml plasma, respectively, p > 0.5; Figures 1C and 1D).
These data suggest that the HIV-specific CD8+ T cells of LTNPs
persist at markedly higher frequencies than those in progressors
with equally low antigen levels in vivo.
Differences in Lytic Granule Loading of Effectors
Expression of effector proteins by HIV-specific CD8+ T cells in
LTNPs and untreated progressors was compared (Figure 2A).
In unstimulated peripheral blood mononuclear cells (PBMCs),
we and others have not detected differences in perforin or gran-
zyme B content of HIV-specific cells between patient groups
(Appay et al., 2002; Migueles et al., 2002; Sandberg et al.,
2001; Zhang et al., 2003). However, upon stimulation, the HIV-
specific CD8+ T cells of LTNPs proliferated and upregulated per-
forin, with substantial increases observed by day 3 and peak
valuesmeasured by day 6 (data not shown). In the present study,
we extended analyses of effector protein expression to include
measurements of Ki67, granzymes A and B, and IFN-g. In addi-
tion, the ability to transport CD107a (lysosome-associatedmem-
brane protein-1) to the cell surface was used as a marker of
degranulation capacity (Betts et al., 2006). Significantly higher
frequencies of HIV Gag-tetramer+ CD8+ T cells were detected
in eight LTNPs compared with eight progressors after a 6 day
stimulation (medians: 33.7% [17.4%–53.3%] versus 3.77%
[0.4%–5.76%], respectively, p < 0.001; Figure 2A and data not
shown). Only the fraction of tetramer+ cells expressing granzyme
B (GrB) or perforin (medians: 87.9% [68.9%–98.4%] versus
61.5% [40.4%–85.3%], p < 0.01, and 85.6% [69.7%–96.6%] ver-
sus46.4% [27.7%–75.4%], p=0.004, respectively) and themean
fluorescence intensity (MFI) of perforin (medians: 3565.5 [1639–
6348] versus 1268 [303–2728], p = 0.01) were significantly higher
in LTNPs compared with those of progressors (Figures 2A–2C).
Furthermore, GrB and perforin expression were very strongly
correlated (R = 0.87, p < 0.001; data not shown). Differences in
the ability of HIV-specific CD8+ T cells to degranulate were not
observed between LTNPs and progressors (p > 0.5; Figures 2B
and2C). These findings support the existence of functional differ-
ences between the CD8+ T cells of LTNPs and progressors, not
in the ability to degranulate but rather in the cytotoxic granule
content (Meng et al., 2006; Migueles et al., 2002; Wolint et al.,
2004).
Relationship between Lytic Granule Loading
of Effectors and Cytotoxicity
We next explored whether differences in cytotoxic granule
content of HIV-specific CD8+ T cells translated into differences
in granule-exocytosis-mediated cytotoxicity. Traditional assaysInc.
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Figure 1. HIV-Specific CD8+ T Cells Persist at Higher Frequencies in LTNPs Compared with Those in Treated Progressors at Equally Low
Levels of HIV-1 RNA
(A) HIV-1 RNA amounts quantified to 1 copy/ml were compared between LTNPs (n = 27) and treated progressors who maintain <50 copies/ml (Rx < 50, n = 50).
(B) Total IFN-g-producing HIV-specific CD8+ T cell frequencies for individuals in (A).
(C) Comparison of HIV-1 RNA amounts between LTNPs (n = 19) and Rx < 50 (n = 28) with detectable viremia (R1 copy/ml).
(D) Total IFN-g-producing HIV-specific CD8+ T cell frequencies for individuals in (C). Horizontal lines indicate median values. Comparisons were made with the
Wilcoxon two-sample test. Only significant p values are shown.of cytotoxicity are unable to differentiate whether differences in
killing are due to differences in CD8+ T cell proliferation. They
are also unable to discern the mechanism of target cell killing.
To determinewhether the increasedGrB and perforin expression
in HIV-specific CD8+ T cells of LTNPs were associated with in-
creased granule-exocytosis-mediated HIV-specific cytotoxicity
on a per-cell basis, we adapted a flow-cytometry-based cytotox-
icity assay that measures GrB-mediated intracellular cleavage of
a cell-permeable fluorogenic substrate in live targets (Packard
et al., 2007). Using this technique, we measured only functional
GrB that had been delivered to the target cell, not inactive GrB
stored within cytotoxic granules. Cytotoxicity mediated by
PBMCs that were either rested overnight (‘‘day 0’’ cells) or incu-
bated with Gag peptides for 6 days (‘‘day 6’’ cells) was assessed
(Figure 3A). Target PBMCs were unpulsed or pulsed with immu-
nodominant histocompatibility leukocyte antigen (HLA) B27- or
B57-restricted Gag optimal epitope peptides. GrB-mediated
substrate cleavage was associated with characteristics of early
death by light scatter, as shown by the increased numbers of
low forward-scatter events in the sampleswith greater GrB activ-
ity (Figure 3B) (Packard et al., 2007). Similar changes in light scat-
ter and GrB substrate cleavage were previously associated with
apoptosis and death of target cells on the basis of annexin-V
staining, morphologic changes such as membrane blebbing,
and cell death on the basis of staining with propidium iodide orImm7-amino-actinomycin D (Packard et al., 2007). To precisely quan-
titate the actual numbers of antigen-specificCD8+ T cells present
in the cultures, we stained aliquots of day 0 and day 6 cells with
the appropriate HLA class I tetramers (Figure 3C). Because the
responses of progressors are broader than those of LTNPs
(Migueles et al., 2000), progressors were further screened with
tetramers containing non-B27-restricted or non-B57-restricted
subdominant epitopes (Table S3). Responses were expressed
as a sum of the individual cytotoxic responses when more than
one epitope was recognized.
The total cytotoxic response of day 0 cells (at a ratio of 25 total
PBMC effector cells to 1 target cell) was low and not significantly
different between LTNPs and progressors (medians: 3.1% ver-
sus 1.9%, respectively, p > 0.5; Figure 3D). However, at the same
E:T ratio, day 6 cells of LTNPs mediated dramatically more
potent cytotoxicity compared to that of progressors (medians:
67% versus 8.1%, respectively, p < 0.001; Figure 3E). Cytotox-
icity was remarkably rapid and complete, with day 6 HIV-specific
CD8+ T cells of LTNPs frequently killing >70% of targets during
the 1 hr incubation. Examination of the outliers suggested an
association among proliferation, upregulation of effector mole-
cules, and cytotoxicity; i.e., cells from the one LTNP with a low
cytotoxic response had undergone less peptide-induced expan-
sion, and the cells of the three HLA B*27+ or 57+ progressors (pa-
tients 21, 132, and 144) with relatively high cytotoxic responsesunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Inc. 1011
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Figure 2. Flow-Cytometry-Based Cytotoxicity Assay Measures Granzyme B Activity in Peptide-Pulsed PBMC Targets
(A and B) Representativemarker expression after 6 day Gag peptide stimulation (A) or 6 day stimulation followed by 6 hr Gag peptide restimulation (B) is shown for
an HLA B*57+ LTNP (top row) and progressor (bottom row). Values indicate the percentage of gated tetramer+ CD8+ T cells.
(C) Summary pie charts showing median percentage expression of GrB, perforin, and CD107 in LTNPs (n = 8, top row) and progressors (n = 8, bottom row).had exhibited greater proliferation after a 6 day peptide stimula-
tion. Cytotoxic capacity on a per-cell basis was similar with day
0 cells from LTNPs or progressors over the shared range of
measured E:T ratios (p = 0.27; Figure 3F). In contrast, with day
6 cells, the cytotoxic-response curveswere significantly different
between LTNPs and progressors (p = 0.03; Figure 3G). The
potent ability of LTNP CD8+ T cells to lyse target cells was highly
efficient and observed down to E:T ratios as low as 2–3:1.
Cytotoxicity of HIV-Infected Primary
Autologous CD4+ T Cell Targets
A clear determination of whether the diminished cytotoxic
responses of progressors relative to LTNPs were due to lower
CD8+ T cell numbers or reduced per-cell cytotoxic capacity
was difficult to establish at the low E:T ratios observed with pep-
tide-pulsed targets. Therefore, we developed a system to mea-
sure CD8+ T cell-mediated cytotoxicity of autologous, acutely
HIV-infected CD4+ T cells (Migueles et al., 2002; Sacha et al.,
2007), permitting a sampling of a broader array of cells specific
for other HIV-encoded peptides and, thereby, the total cytotoxic1012 Immunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Iresponses at higher E:T ratios. In addition, we used a LIVE DEAD
reagent that enabled separation of three cell populations: effec-
tors, targets, and targets that were dead prior to the 1 hr coincu-
bation (see Experimental Procedures; Figure 4A). In this assay,
CD8+ effector frequency (based upon IFN-g secretion) and target
cell GrB activity were measured in parallel (Figures 4B and 4C).
After analysis for GrB activity, the fraction of targets expressing
HIV p24 was quantified in the same samples by flow cytometry,
and the infected CD4+ T cell elimination (ICE) was determined
as another measure of cytotoxic T cell efficacy (Figure 4D). The
association between GrB target cell activity and cell death in
this system was verified by the observation of increased mem-
brane permeability to propidium iodide only in the infected target
cells exhibiting increased GrB activity (Figure S1). Furthermore,
the responses measured by GrB activity or ICE were abrogated
when CD8+ T cells were incubated with autologous uninfected
or heterologous, HLA-mismatched infected targets, confirming
that cytotoxicity was mediated by HIV-specific CD8+ T cells in
an HLA-restricted fashion (Figure S1). The median amount of
GrB or ICE activity in six uninfected controls was 1.2% andnc.
Immunity
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permitted accurate measurements of HIV-specific CD8+ T cell
frequency, delivery of functional granzyme B into infected
lymphoblast targets, and infected target cell frequency and
elimination.
With day 0 CD8+ T cells (at a ratio of 25 total CD8+ T cells to
1 target cell), the cytotoxic responses measured by GrB activity
or ICE were comparable between patient groups, except for sig-
nificant differences in ICEbetween LTNPsandRx<50 (p < 0.001;
Figures 5Aand5B). BackgroundGrBactivitywas low in response
to day 0 or day 6 CD8+ T cells (4.7% and 7.4%, respectively). Al-
though cytotoxicity measured by either method was significantly
greaterwith day6 cells comparedwith day0 cells for eachpatient
group, day 6 CD8+ T cells derived from LTNPs had markedly
greater cytotoxic capacity than either progressors or Rx < 50
(p < 0.001 for all comparisons; Figures 5A and 5B). A very strong
correlation was noted between GrB target cell activity and ICE
when day 6 cells were used (R = 0.79, p < 0.001; Figure 5C). In
a subset of 17 patients, perforin content was tightly correlated
with GrB target cell activity and ICE (R = 0.92, p < 0.001 and
R = 0.83, p < 0.001, respectively; Figures 5D and 5E). These
results suggest that cytotoxicity measured by either method is
highly dependent upon memory cell lytic granule loading.
We also analyzed the above data on a per-cell basis by using
measured E:T ratios. With day 0 cells, target cell GrB activity
was not significantly different between LTNPs and progressors
(p > 0.5; Figure 6A). ICE was modestly but significantly greater
in LTNPs than inprogressors over the common rangeof E:T ratios
(p=0.03; Figure 6B). In contrast to the resultswithday0cells,GrB
activity and ICEmediated byday 6 cellswere significantly greater
for LTNPs thanprogressors by a constant 18%and40%, respec-
tively, over the common range of E:T ratios (p < 0.001; Figures 6C
and 6D). In Figure 6C, the slopes of the trend lines were not sig-
nificantly different from zero. The GrB activity observed probably
reachedaplateau for different reasons for the twopatient groups.
Considering that 40%–60% of the total target cells are infected,
this plateau probably occurred for LTNP-derived day 6 cells
because GrB activity approached the theoretical maximum at
very low measured E:T ratios (Figure 6C). However, cytotoxicity
mediated by day 6 cells of progressors, measured either by
GrB activity or ICE, never reached the levels observed in LTNPs,
even at high E:T ratios. Theminimal overlap of E:T ratios between
Rx < 50 and the other groups precluded meaningful compari-
sons. However, the median measured E:T for Rx < 50 was
1.1:1, and at this ratio, neither GrB activity nor ICE approached
the levels observed in LTNPs, but rather was similar to those of
progressors. Diminished per-cell cytotoxicity in progressors
compared to LTNPs was not due to death of HIV-specific CD8+
T cells, given the persistence of high frequencies of IFN-g+ cells
6 hr later. The differences in cytotoxic responses between LTNPs
and other patient groups were consistent with, and more dra-
matic than, those measured against peptide-pulsed targets.
These data suggest that the cytotoxic capacity of HIV-specific
CD8+ T cells of LTNPs is attributable not merely to increases in
cell numbers, but also toqualitative changes in effector cells. Fur-
thermore, the observation that the cytotoxic capacities of these
cells are not substantially restored in patients with suppressed
viremia due to ART supports the idea that diminished cytotoxicity
of untreated progressors’ cells is not simply a consequence ofImmhigh amounts of antigen in the chronic phase of infection. These
results suggest that elimination of autologous HIV-infected CD4+
T cells mediated by the granule-exocytosis pathway segregates
with immunologic control of HIV. They also demonstrate that lytic
granule contents of memory cells are an important determinant
of cytotoxicity that must be induced for maximal per-cell killing
capacity.
Diminished Cytotoxic Capacity of HIV-Specific
CD8+ T Cells of Progressors Is Reversible
Recent data have suggested that disrupted HIV-specific CD8+
T cell proliferation in progressors is associated with increased
surface programmed death-1 (PD-1) (Day et al., 2006; Petrovas
et al., 2006; Trautmann et al., 2006) and decreased CD127
(IL-7Ra chain) (Paiardini et al., 2005) expression. For this reason,
these surface markers were examined in our cohorts. We found
significant increases in the percentage of PD-1+ HIV HLA-tetra-
mer+ cells (p = 0.02) and significant reductions in the percentage
expressing CD127 (p = 0.004) in 18 viremic progressors com-
pared with 16 LTNPs (Figure S2A). Although these markers
were weakly but significantly correlated with viral-load measure-
ments in these 34patients (FigureS2B), PD-1 andCD127expres-
sion in eight Rx < 50 approached the levels observed in LTNPs
(p > 0.5; Figure S2A). Because immune-mediated restriction of
HIV replication is not restored in Rx < 50 (Davey et al., 1999; Ortiz
et al., 2001), these data suggest that the changes in PD-1 or
CD127 expression on HIV-specific CD8+ T cells with therapy
areaneffect of viremia, consistentwith some recent observations
(Rehr et al., 2008; Streeck et al., 2008).
Several features of HIV-specific CD8+ T cells of progressors
are consistent with some states of anergy, including diminished
proliferative capacity and IL-2 production (Betts et al., 2006;
Migueles et al., 2002; Zimmerli et al., 2005). A number of stimuli
have been reported to overcome the anergic state (reviewed in
Schwartz, 2003). Stimulation with phorbol-12-myristate-13-ace-
tate and ionomycin (PMA+Io), followed by a period of rest prior to
restimulation with HIV peptides and IL-2 (day 24 PMA+Io), pro-
duced frequencies of HIV-specific CD8+ T cells that were greater
than those produced by treatment with anti-CD3 and anti-CD28,
a period of rest, and restimulation with HIV peptides and IL-2
(day 24 CD3+CD28, p = 0.03; Figure S3, Figures 7A and 7B,
and data not shown). To analyze whether these frequencies
translated into changes in cytotoxic capacity, we performed a
regression analysis of GrB activity on the log of the E:T ratio
for the three sets of conditions (day 24 PMA+Io, day 24
CD3+CD28, and cells stimulated for 6 days with Gag peptides
[day 6 Gag]; Figures 7C–7E). For a fixed E:T ratio of 1, there
was a statistically significant difference for day 24 PMA+Io
versus day 24 CD3+CD28 (51.4% versus 28.6%, p < 0.05) and
for day 24 PMA+Io versus day 6 Gag (51.4% versus 19.8%,
p < 0.001), but not for day 24 CD3+CD28 versus day 6 Gag
(p > 0.5). Therefore, unlike cells treated with anti-CD3, anti-
CD28, and IL-2, PMA+Io-treated cells mediated significantly
greater cytotoxicity of peptide-pulsed targets compared with
D6 Gag cells, in a manner that overlapped with activity of cells
from LTNPs (Figures 7C–7E).
The recovery of proliferation of HIV-specific CD8+ T cells of
progressors by PMA+Io and prior descriptions of diminished
IL-2 production by these cells (Betts et al., 2006; Zimmerli et al.,unity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Inc. 1013
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HIV-Infected CD4+ T Cell Elimination2005) suggested that there may be some disruption of the calci-
neurin-nuclear factor of activated T cells (NFAT) pathway. Nu-
clear translocation of NFAT is an important early signal leading
to cell division and IL-2 transcription (reviewed in Sundrud and
Rao, 2007). We examined this pathway by using a technique
that allows for quantitative image analysis and flow cytometry
in a single platform (Figure 7F). We observed greater NFAT
nuclear translocation in the HIV-specific cells of LTNPs (median:
77.2%) than those of untreated (52.3%, p = 0.05) or treated
progressors (26.1%,p=0.002;Figure7G).Althoughonly a limited
number of specificities can be examined by this technique and
there is some overlap between patient groups, these data sug-
gest that agreater fraction ofHIV-specific cells of LTNPsmaintain
Figure 3. HIV-Specific CD8+ T cells from LTNPs Mediate Greater Lysis of Peptide-Pulsed Targets than Cells from Progressors
(A) GrB activity in PBMC targets pulsedwith three B57-restrictedGag epitopes after adding day 0 (D#0, center column) or day 6 (D#6, right column) cells in a B*57+
LTNP (top row) and progressor (bottom row). Values indicate percentages of targets with increased fluorescence due to GrB substrate cleavage. Red values
indicate GrB activity after subtracting background (left column for D#0 cells and not shown for D#6 cells).
(B) Light-scatter characteristics of gated targets from (A).
(C) Measurement of peptide-specific CD8+ T cells with three B57 HIV tetramers complexed to the same peptides used in (A) and (B). Values indicate the percent-
age of gated CD8+ T cells.
(D and E) Summary data of the total cytotoxic response (sum of the individual responses when more than one epitope was recognized) with D#0 cells of LTNPs
(red circles, n = 8) and progressors (blue circles, n = 15, [D]) or D#6 cells of LTNPs (n = 16) and progressors (n = 24, [E]). Horizontal lines indicate median values.
Comparisons were made with the Wilcoxon two-sample test. Only significant p values are shown.
(F andG) Data in (D) and (E) plotted against E:T ratios on the basis of HIV-tetramer frequencies (C). Curves represent trends for LTNPs (red) and progressors (blue).
Analysis of covariance was used for quantifying the logit of GrB activity over the range of logged E:T ratios.
Figure 4. HIV-Specific CD8+ T Cell Cytotox-
icity Measured by Granzyme B Delivery or
Infected CD4+ T Cell Elimination
(A) Gating scheme for identifying three cell popula-
tions (right plot) is shown: CD8+ T cell effectors (tar-
get LIVE DEAD label negative), CD4+ T-lymphoblast
targets (LIVE DEAD label positive), and cells that
have died prior to the incubation of CD8+ T cells
and CD4+ T cell targets (LIVE DEAD label bright,
off scale).
(B) D#0 and D#6 HIV-specific CD8+ T cells are mea-
sured as percentages of CD3+ CD8+ lymphocytes
expressing IFN-g.
(C)GrBactivity in gated targets after adding nocells,
D#0 cells, or D#6 CD8+ cells in a representative
LTNP. Red values indicate percentages of targets
with increased GrB activity after subtracting back-
ground values (data not shown), whichwere derived
from measurements of GrB activity in uninfected
targets mixed with D#0 (for middle panel) or D#6
cells (for bottom panel), respectively.
(D) Cells from (C) after fixation, permeabilization,
and staining for CD4 and intracellular p24 expres-
sion. Quadrant values indicate percentages of
gated targets. Infected cell elimination (ICE) was
calculated with p24+ targets (sum of upper quad-
rants) as described in Experimental Procedures.
the ability to translocate NFAT to the
nucleus upon antigen encounter.
DISCUSSION
Although HIV-specific CD8+ T cells have
long been suspected of mediating immu-
nologic control in LTNPs, qualitative features of the CD8+ T cell
response that clearly segregate with LTNPs and might mediate
effective control of HIV have remained poorly understood. The
efficient elimination of an HIV-infected CD4+ T cell via the gran-
ule-exocytosis pathway involves a series of events that include
T cell activation, expansion, upregulation of effector molecules,
degranulation, and delivery of lytic granule contents to the target.
In the present study, we examined these functions in the HIV-
specific CD8+ T cells of patients with and without immunologic
control of HIV. To control for differences in proliferation or death
of effector or target cells or effects not mediated by CD8+ T cells
or lytic granules, we applied assays that measured effector cell
frequency, infected target frequency, delivery of functional GrBImmunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Inc. 1015
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Figure 5. HIV-Specific CD8+ T Cells from LTNPs Mediate Greater Lysis of HIV-Infected CD4+ T Cell Targets Compared with Progressors
(A andB) Summary data of the total cytotoxic responsewith GrB activity (A) or ICE (B) in LTNPs (n = 18), progressors (n = 18 and 19 in [A] and [B], respectively), and
Rx < 50 (n = 16). Data are representative of three experiments. Comparisons were made with the Wilcoxon two-sample or signed-rank tests. Horizontal lines
indicate median values. Only significant p values are shown.
(C) With D#6 CD8+ T cells, GrB target cell activity correlates directly with ICE (n = 52).
(D and E) With D#6 CD8+ T cells, the perforin content of HIV-specific CD8+ T cells directly correlates with both GrB target cell activity (D) and ICE (E) in a subset of
LTNPs, viremic progressors, and Rx < 50 (n = 17). Statistical analyses were performed with the Spearman correlation.into targets, and HIV-infected CD4+ T cell elimination. The
HIV-specific CD8+ T cells of LTNPs were found to have extraor-
dinary cytotoxic capacity on a per-cell basis. The potent ability of
HIV-specific CD8+ T cells of LTNPs to eliminate HIV-infected
CD4+ T cells was mediated by delivery of GrB to target cells.
These data provide an effector function and mechanism that
clearly segregate with LTNPs.
Perhaps as importantly, these results have implications that
may extend to other chronic viral infections of experimental an-
imals or humans. It has been the accepted paradigm for some
time that memory cells maintain full cytotoxic capacity (reviewed
in Seder and Ahmed, 2003; Trambas and Griffiths, 2003). On the
basis of this model, re-expansion does not involve qualitative
changes in cytotoxic capacity but rather is primarily quantitative,
merely reflecting increases in the actual numbers of effector
memory cells. However, a determination of whether increases
in lytic granule content translate into qualitative changes has
been limited by the lack of antibodies for some lytic granule
proteins in mice and a lack of assays that measure cytotoxicity
on a per-cell basis. In the present study, there were dramatic
increases in per-cell killing capacity over 6 days associated
with increases in perforin and GrB. This observation strongly
suggests that restimulation of memory cells involves not only
quantitative expansion, but also increases in lytic granule con-
tent that provide large qualitative increases in cytotoxic capacity.
At first inspection, it was surprising that the greatest differ-
ences in cytotoxic function between patient groups were1016 Immunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Iobserved after several days of exposure to autologous HIV-
infected CD4+ T cells. However, the function of CD8+ T cells
should probably be interpreted in the context of levels of antigen
and likelihood of recent stimulation in vivo. The measurement of
the CD8+ T cell response in LTNPs, treated progressors, or
vaccinees is performed under conditions of low or absent anti-
gen. Thus, an examination of such a recall response involves
measurements of activation and cytokine secretion over several
hours, cell-cycle progression and loading of effector molecules
over several days, and target cell recognition and degranulation
over 1–4 hr. Our results suggest that, under conditions of low
amounts of antigen, measurements of virus-specific cell fre-
quency and direct ex vivo cytotoxicity may not provide the best
measure of the ability to restrict virus replication. Rather, prolifer-
ative capacity, upregulation of effector molecules, and target cell
elimination are all important functions of the recall response of
memory cells that should be considered.
This study also documents qualitative defects of the
HIV-specific CD8+ T cells of progressors. We observed that the
HIV-specific CD8+ T cells of Rx < 50, unlike those of LTNPs, re-
quire ongoing exposure to antigen for persistence, reminiscent
of some recent findings in mice acutely or chronically infected
with LCMV (Shin et al., 2007). In the present study and prior
work, we did not detect defects in early events of HIV-specific
CD8+ T cell activation in progressors, such as recognition of
autologous virus-infected cells and cytokine production. Dimin-
ished HIV-specific cytotoxicity of viremic progressor or Rx < 50nc.
Immunity
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Figure 6. Day 6HIV-Specific CD8+ T Cells of LTNPsMediate Greater Cytotoxicity of HIV-Infected CD4+ TCell Targets on a Per-Cell Basis than
Cells of Progressors
(A–D) GrB activity or ICE with D#0 (A and B) or D#6 (C and D) cells plotted against true E:T ratios based on measurements of IFN-g-secreting cells (Figure 4B) and
p24-expressing targets (Figure 4D, top panel). GrB activity is shown after subtraction of background. Analysis of covariance was used for quantifying the differ-
ence in GrB activity and ICE in LTNPs and progressors over the range of E:T ratios.CD8+ T cells relative to those of LTNPs was also not caused by
defects in degranulation. HIV-infected CD4+ T cell elimination
by progressors’ cells did not exceed 60%, even at very highmea-
sured E:T ratios. Diminished killing by progressors’ CD8+ T cells
was not due to death of cytotoxic cells because they produced
IFN-g 6 hr later. Taken together, these data suggest that dimin-
ished killing capacity of HIV-specific CD8+ T cells of progressors
is due to deficient loading of lytic granules and is likely to be an
important mechanism accounting for the loss of immunologic
control of HIV in these patients.
We also observed that considerable expansion and cytotoxic
potential can be restimulated from the PBMCs of progressors,
suggesting that these properties are not permanently lost by
deletion, anergy, or replicative senescence. The recovery of pro-
liferation by PMA+Io described here and the previously reported
decreases in IL-2 production by HIV-specific CD8+ T cells of pro-
gressors (Betts et al., 2006; Zimmerli et al., 2005) suggested that
theremight be some disruption of calcium flux or the calcineurin-
NFAT pathway. Nuclear translocation of NFAT is an importantImmearly event in cell proliferation and IL-2 transcription (reviewed
in Sundrud and Rao, 2007). Although we observed that a signifi-
cantly greater proportion of HIV-specific CD8+ T cells of LTNPs
translocated NFAT upon peptide stimulation, there was consid-
erable overlap between patient groups. It is possible that larger
differences in NFAT translocation would be observed between
patient groups, similar to differences observed with the ICE
assay, if a larger number of specificities were sampled in assays
using infected cells instead of peptide stimuli.
These results begin to address some of the cause-and-effect
relationships between the cellular immune response and HIV
viremia. Lowering of viral antigen levels by antiretroviral therapy
is sufficient to restore HIV-specific CD4+ T cell proliferation, IL-2
production, and surface phenotype to levels observed in LTNPs
(Tilton et al., 2007). It is also sufficient to restore PD-1, CD127, or
IL-2 expression by HIV-specific CD8+ T cells in results presented
here and some recent studies (Rehr et al., 2008; Streeck et al.,
2008). Because immunologic control of HIV replication is not
restored in treated-progressor cohorts, these results suggestunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Inc. 1017
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Figure 7. Phorbol Ester and Calcium Ionophore Treatment Produces Greater Increases in Cytotoxic Capacity of HIV Tetramer+ CD8+ T Cells
than Treatment with CD3+CD28 Antibodies
(A–D) After anti-CD3+anti-CD28 (A and C) or PMA+Io (B and D) treatment, PBMCs were incubated for 18 days and then stimulated with Gag peptides and IL-2
(2 IU/ml) for 6 more days. Some cells, which had been CFSE labeled on day 18, were stained with three B57- or 2 B27-HIV Gag tetramers and assessed for
proliferation on day 24 (A and B). Quadrant values indicate percentages of gated CD8+ T cells. GrB activity in peptide-pulsed targets was measured with day
24 cells (C and D). Values indicate percentages of targets after subtracting background.
(E) Summary data of GrB activity plotted against E:T ratios of D#6 cells incubated with Gag peptides or 24 days after treatment with CD3+CD28 antibodies or
PMA+Io in three B*27+ and seven B*57+ progressors. Linear mixed and generalized estimating equations approaches were used for inference.
(F) Representative plots of Image Stream analysis of CD8+ T cells incubated in medium alone, HIV KF11 peptide, and PMA+Io control conditions. Representative
images corresponding to quadrants are shown in lower panels.
(G) Summary data of NFAT nuclear translocation in HIV tetramer+ cells for LTNPs (n = 17), viremic progressors (n = 22), and Rx < 50 (n = 13). Horizontal lines
indicate median values. Comparisons were made with the Wilcoxon two-sample test. Only significant p values are shown.changes in these parameters are a consequence of viremia and
not a cause of the loss of immunologic control. However, we
have not observed a similar restoration of HIV-specific CD8+
T cell proliferative capacity, lytic granule loading, or cytotoxic
potential here or in prior work. It remains possible that one or
several host or viral factors may increase peak viremia during
acute infection, resulting in disruption of proliferative or cytotoxic
capacity. However, this is a separate issue because the subject
of the present study is to determine those functions that are dis-
rupted during the chronic phase of infection. The results of the
present study suggest that proliferative and cytotoxic capacity
are disrupted functions of the HIV-specific CD8+ T cell response.
A formal demonstration that cells with these functions intact1018 Immunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Icause immunologic control of lentiviral replication would require
passive-transfer studies in humans or experimental animals.
Perhaps most importantly, data from the present study sug-
gest that induction of cells able to undergo rapid expansion
and mediate cytotoxicity upon antigen encounter are possible
goals for HIV vaccines. Most vaccine trials and studies of chronic
infection have relied heavily upon detection of HIV-specific cells
by cytokine secretion in response to high concentrations of non-
optimal peptides with excess costimulatory antibodies and vary-
ing degrees of intercell contact. The HIV-infected cell assay used
in the present study permits measurement of the response in the
context of maintained major histocompatibility complex (MHC)-
peptide stoichiometry, Nef-mediated MHC downregulation, andnc.
Immunity
HIV-Infected CD4+ T Cell Eliminationnaturally processed peptides. The findings of the present study
demonstrate the qualitative features of an effective virus-specific
CD8+ T cell response that should be considered in the testing
of the next generation of prophylactic and therapeutic vaccines
for HIV.
EXPERIMENTAL PROCEDURES
Study Subjects
Subjects signed Investigational Review Board-approved informed consent
documents. HIV infection was documented by HIV-1 and 2 immunoassay.
LTNP criteria include the following: clinically healthy status, negative history
for opportunistic diseases, stable T cell counts, set point HIV-1 RNA amounts
< 50 copies/ml (bDNA assay, Bayer Diagnostics, Tarrytown, NY, USA), and no
ongoing ART (Table S1). Progressors, defined as patients with a progressive
decline in CD4+ T cell counts and/or current or previously documented poor
restriction of virus replication (HIV-1 RNA amounts > 1000 copies/ml) when
not receiving antiretroviral therapy, were divided into subgroups based on
duration of infection, HIV-1 RNA set points, and treatment status (Table S2).
Untreated patients were either ART naive or had been off ART for at least six
months prior to leukapheresis. Treated patients received continuous ART,
and patients with <50 HIV RNA copies/ml had been suppressed for a median
of 5 years (range 2–11 years). HLA typingwas performed by sequence-specific
hybridization as described previously (Migueles et al., 2000).
HIV-1 RNA Determination
In a subgroup of LTNPs and treated patients with <50 copies/ml, single-copy
assays were performed as described (Palmer et al., 2003).
HIVSF162-Infected Autologous CD4
+ T Cell Targets
PBMCs were obtained as described previously (Migueles et al., 2002). CD4+
T cells were positively selected from cryopreserved PBMCs by magnetic
automated cell sorting (AutoMACS, Miltenyi Biotec, Auburn, CA, USA) and
polyclonally stimulated prior to infection as previously described (Migueles
et al., 2002; Sacha et al., 2007).
Granzyme B Cytotoxicity Assay
In peptide-based assays, cryopreserved PBMC targets were resuspended
at 2 3 106 cells/ml in 0.5% human serum (HAB; Gem Cell Gemini Bio-
Products, Sacramento, CA, USA) RPMI medium and incubated in medium
or medium containing optimal peptides (2.5–5 mM for each peptide, Multiple
Peptide Systems, San Diego, CA, USA; Table S3) for 1 hr at 37C. During
the final 15 min, targets were stained with the TFL4 label (GranToxiLux,
OncoImmunin, Gaithersburg, MD, USA) (Packard et al., 2007). Targets were
then labeled with a LIVE DEAD Fixable Violet Stain Kit (Molecular Probes, Invi-
trogen Detection Technologies, Eugene, OR, USA) per the manufacturer’s
instructions. Effector PBMCs, which had either been rested overnight (day 0,
D#0) or stimulated with pooled HIV-1 Gag, Pol, Nef, or Env clade B 15-mer
peptides (2 mg/ml of each peptide, National Institutes of Health AIDS Research
and Reference Program, Bethesda, MD, USA) corresponding to the relevant
optimal epitopes (day 6, D#6), were combined with targets at an E:T ratio of
25:1 at 37C for 1 hr. The GranToxiLux killing assay was conducted per the
manufacturer’s protocols (OncoImmunin) except where otherwise noted.
The GrB substrate was used at a 43 dilution. Aliquots of D#0 and D#6 cells
were stained with the appropriate HLA class I tetramers for determining E:T
ratios on the basis of actual numbers of peptide-specific cells.
In assays using CD4+ targets infected with HIVSF162, D#0 cells and D#6 cells
(coincubated with infected targets for 6 days) underwent negative selection of
CD8+ T cells (CD8+ T cell Isolation Kit II, Miltenyi Biotec). Targets were labeled
with the LIVE DEAD violet stain as described above. After analysis of GrB ac-
tivity by flow cytometry, cells were treated with Cytofix/Cytoperm (BD Biosci-
ences, San Jose, CA, USA) prior to staining for confirmation of infection and
measurement of elimination of p24-expressing cells. The measured effector
numbers were the frequencies of IFN-g+ CD8+ T cells detected in parallel.
The true target numbers were measured on the basis of the total percentages
of p24+ cells. Infected CD4+ T cell elimination (ICE) was calculated as follows:Imm([% p24 expression of infected targets%p24 expression of infected targets
mixed with D#0 or D#6 cells]O% p24 expression of infected targets) 3 100.
Reversal Experiments
PBMCs were resuspended in 10% HABmedium to a concentration of 43 106
cells/ml and stimulated with phorbol-12-myristate-13-acetate (PMA, 6.5 nM;
Calbiochem, Darmstadt, Germany, USA) and ionomycin (Io, 0.2 mM; Sigma
Aldrich, St. Louis, MO, USA) or CD3 antibodies (Orthoclone OKT3, 1 mg/ml;
Ortho Biotech, Bridgewater, NJ, USA) and CD28 antibodies (1 mg/ml; BD
Biosciences) at 37C. At 6 hr, cells were incubated with DNase I (10 U/ml;
Invitrogen, Carlsbad, CA, USA) at 37C, washed, resuspended in 10% HAB
medium without (in the case of PMA+Io stimulated) or with CD3+CD28 anti-
bodies and plated in culture plates with 96 1-ml-deep wells (PGC Scientifics,
Frederick, MD, USA) for 6, 12, or 18 days at 37C. Unstimulated PBMCs
were also plated as controls. Medium was replaced every 6 days. Pooled
HIV-1 Gag peptides with or without IL-2 (2 or 20 IU/ml; Roche Diagnostics,
Manheim, Germany) were added for 6 additional days prior to tetramer stain-
ing. Some wells from each condition were labeled with CFSE and analyzed for
proliferation as described previously (Migueles et al., 2002).
Flow Cytometry
Measurements of intracellular accumulation of lytic granule contents, degran-
ulation, and proliferation were performed as previously described (Betts et al.,
2006;Migueles et al., 2002). Surface and/or intracellular stainingwas donewith
the following antibodies: fluorescein isothiocyanate (FITC)-conjugated anti-
CD3, phycoerythrin (PE)-conjugated anti-CD8, peridinine chlorophyll protein
(PerCP)-conjugated anti-CD3, allophycocyanin (APC)-conjugated anti-IFN-g
or anti-CD4, Pacific Blue-conjugated anti-PD-1 and anti-GrA, PE Cy7-conju-
gated anti-perforin, Alexa 700-conjugated anti-GrB, and APC Cy7-conjugated
anti-Ki67 (BD Biosciences). APC or PE-labeled HLA class I tetramers (Table
S3), p24 antibodies (Kc57 RDI), and PE Alexa 700-conjugated anti-CD127
were purchased fromBeckmanCoulter (Fullerton,CA,USA). Sampleswere an-
alyzed on a FACSAria multilaser cytometer (BD Biosciences) with FACSDiva
software, and 50,000–23 106 CD3+ CD8+ lymphocyte events were collected.
In cytotoxicity experiments, 5,000–8,000 target events were collected. Data
were analyzed with FlowJo software (TreeStar, San Carlos, CA, USA).
Measurement of NFAT Translocation
PBMCswere stimulated at 23106 cells perwell in a total volumeof 500ml. Cells
were incubated in medium alone, in medium containing optimal peptides (final
concentration 2 mg/ml each), or in PMA+Io (final concentration 400 nM each).
Plates were incubated at 37C for 30 min, and then cells were transferred to
V-bottom tubes and chilled on ice for 10 min. Cells were then centrifuged
and stained with anti-CD8 PE-Alexa 610 (Invitrogen) and tetramer for 30 min
at 4C.Cellswere thenwashed, fixedwith 4%paraformaldehyde, andpermea-
bilizedwith 500 ml of a 1:1mix of Phosflowbuffers II and III (BDBiosciences) ac-
cording to the manufacturer’s protocol. The cells were then stained with Alexa
488-labeled anti-NFAT antibody (BD Biosciences), washed, and resuspended
in 120 ml of PBS+BSAcontaining 5 mMofDRAQ-5 nuclear stain (Alexis, Lausen,
Switzerland).
Cell images were collected with an Image Stream 100 (Amnis, Seattle, WA,
USA), and analysis was performed as recently described (George et al.,
2006). Briefly, the ratio of the NFAT integral in the nuclear mask to the NFAT
integral in the cytoplasmic mask was then used to create the similarity score.
The percent of tetramer+ cells that translocated on the basis of similarity score
was measured on 140,000 images per condition and expressed as %M, %P,
and%PMA+Io (cells incubated inmedium alone, with peptide, or with PMA+Io,
respectively). Thepercent ofmaximum translocationwascalculated as follows:
(%P%M)/(%PMA+Io%M)3 100=percentage ofmaximum translocation.
Statistical Analysis
The Wilcoxon signed-rank test was used for comparing paired data. Indepen-
dent groups were compared by the Wilcoxon two-sample test. Correlation
was determined by the Spearman rank method. The Bonferroni method was
used for adjusting p values for multiple testing. Analysis of covariance with ap-
propriately transformed variables was used for quantifying the difference in
GrB activity and ICE of peptide-pulsed and HIV-infected CD4+ T cell targets
in LTNPs and progressors over the range of E:T ratios. Linear mixed modelsunity 29, 1009–1021, December 19, 2008 ª2008 Elsevier Inc. 1019
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HIV-Infected CD4+ T Cell Eliminationand generalized estimating equations were used for analysis of the PMA+Io
or anti-CD3+anti-CD28 reversal experiments.
SUPPLEMENTAL DATA
Supplemental Data include three tables and three figures and can be
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